McGill J, Tormey P
Am J Med. 1982 Jul 20;73(1A):286-9. doi: 10.1016/0002-9343(82)90107-3.
Acyclovir has veen shown to have potent antiviral activity against both herpes simplex and herpes zoster viruses, especially the former, with low cellular toxicity, preferentially affecting virally infective cells by inhibiting viral DNA synthesis [1,2]. In experimental herpes simplex corneal infection, acyclovir has been found to be effective [3,4] and in early clinical trials it has been found to be at least as good as idoxuridine [5-7]. Acyclovir has also been found to have antiviral activity against the herpes zoster virus in tissue culture [1] and to affect favorably the course of the disease in immunosuppressed patients [8]. This paper describes the use of acyclovir in patients with either herpes simplex or herpes zoster ocular infections. Topical acyclovir has been compared with adenine arabinoside in the treatment of herpes simplex corneal ulceration in a coded clinical trial. The use of acyclovir will also be described in patients with complicated herpes simplex eye disease. Our initial results with topical acyclovir in herpes zoster keratouveitis are also described.
阿昔洛韦已被证明对单纯疱疹病毒和带状疱疹病毒均具有强大的抗病毒活性,尤其是对前者,且细胞毒性低,通过抑制病毒DNA合成优先影响病毒感染细胞[1,2]。在实验性单纯疱疹性角膜感染中,已发现阿昔洛韦有效[3,4],并且在早期临床试验中,已发现其至少与碘苷一样有效[5-7]。在组织培养中也发现阿昔洛韦对带状疱疹病毒具有抗病毒活性[1],并对免疫抑制患者的疾病进程有积极影响[8]。本文描述了阿昔洛韦在单纯疱疹或带状疱疹眼部感染患者中的应用。在一项编码临床试验中,已将局部用阿昔洛韦与阿糖腺苷用于治疗单纯疱疹性角膜溃疡进行了比较。还将描述阿昔洛韦在单纯疱疹性眼病并发症患者中的应用。还介绍了我们使用局部用阿昔洛韦治疗带状疱疹性角膜葡萄膜炎的初步结果。